XRTX · XORTX Therapeutics Inc.

XORTX Therapeutics Inc. reports that its preliminary, unaudited estimate of stockholders’ equity stands at approximately $4.1 million as of the filing date, which management states exceeds the minimum requirement for continued listing on the Nasdaq Capital Market. This assessment incorporates the Company’s estimated equity position as of March 31, 2026, the completed acquisition of Vectus Biosystems Limited’s VB4-P5 asset on April 13, 2026, and estimated operating results through the second quarter of 2026 to date. Investors should note that these figures are subject to revision following the completion of financial closing processes and preparation of unaudited condensed consolidated financial statements for the first quarter ended March 31, 2026. The Company cautions that actual results may differ materially and emphasizes that this preliminary information is not a substitute for finalized financial statements.